Universität zu Köln

Ferdinandus, J., Oertel, M., Eichenauer, D. A., Meissner, J., Engert, A. and Borchmann, P. (2022). Advanced-stage Hodgkin lymphoma. Onkologie, 28 (10). S. 889 - 901. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 2731-7234

Full text not available from this repository.

Abstract

Background In recent years, positron emission tomography (PET)-adapted protocols and new agents such as brentuximab vedotin are increasingly used as part of first-line protocols of advanced-stage Hodgkin lymphoma (HL). Objectives This manuscript reviews guideline-based therapy and available trial data in advanced-stage HL. Materials and methods This is a narrative review. Results The German HL guideline recommends interim PET2-guided (PET after 2 cycles) chemotherapy using 4 cycles of eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) for PET2-negative patients up to 60 years of age with advanced HL and 6 cycles eBEACOPP for PET2-positive patients. Furthermore, patients with PET-positive residual lymphoma should receive consolidation radiotherapy with 30 Gy. This is based on effective tumor control and short duration of therapy of 3 months in most patients. For elderly patients, treatment with 2 cycles of ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) followed by 4 cycles of AVD and irradiation of PET-positive residuals is recommended. Conclusions Advanced-stage HL is curable in more than 90% of cases. The goal of current scientific efforts is to reduce toxicity while maintaining efficacy by including immune checkpoint inhibitors.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Ferdinandus, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Oertel, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichenauer, D. A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Meissner, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-676788
DOI:	10.1007/s00761-022-01186-9
Journal or Publication Title:	Onkologie
Volume:	28
Number:	10
Page Range:	S. 889 - 901
Date:	2022
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	2731-7234
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language OPEN-LABEL; BRENTUXIMAB VEDOTIN; RANDOMIZED PHASE-3; ADAPTED TREATMENT; HD15 TRIAL; CHEMOTHERAPY; SURVIVAL; VINBLASTINE; DOXORUBICIN; BEACOPP Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/67678